2019
174O Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance)
Fernandez-Martinez A, Tanioka M, Fan C, Parker J, Hoadley K, Krop I, Partridge A, Carey L, Perou C. 174O Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical trial (Alliance). Annals Of Oncology 2019, 30: v55. DOI: 10.1093/annonc/mdz240.Peer-Reviewed Original ResearchPathologic complete responseEvent-free survivalGene expression signaturesPrognostic valueBreast cancerCALGB 40601Clinical trialsSignature scoreImmune-mediated anti-tumor responseHigher pathologic complete responseTumor-infiltrating lymphocyte densityNeoadjuvant treatment strategiesAnti-tumor responseB cell signaturesB cell receptor repertoireExpression signaturesImmune-related signaturePre-treatment samplesDual HER2Neoadjuvant studiesCombination regimenComplete responseLymphocyte densityClinical parametersUnivariate analysis
2014
An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer.
Bianchini G, Rossi G, Callari M, Iwamoto T, Galeota E, Karn T, Kelly C, Zambetti M, Santarpia L, Pusztai L, Gianni L. An immune-related signature for prediction of risk of late recurrences beyond proliferation and ER-related genes in ER-positive breast cancer. Journal Of Clinical Oncology 2014, 32: 530-530. DOI: 10.1200/jco.2014.32.15_suppl.530.Peer-Reviewed Original ResearchER-positive breast cancerImmune-related signatureLate recurrencePrediction of riskBreast cancerRecurrenceCancer
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply